Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

Abstract: There is disclosed derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).

Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.

Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a c-Met target conjugated at both Cys sites in the hinge region of an IgG antibody. There is further disclosed a method for treating a breast cancer comprising providing an effective amount of a c-Met ADC.

Abstract: There is disclosed a calicheamicin antibody drug conjugate comprising a linking amidoacetyl group covalently bound to a sugar moiety on calicheamicin or linking to sulfur atom on calicheamicin through disulfide bond.

Abstract: There is disclosed antibody drug conjugates having anthracycline derivative drug moieties that provide improved safety and cell killing efficacy, wherein the anthracycline derivative drug moieties substitute an hydroxymethyl ketone moiety for an hydrazide or hydroxamate moiety. The disclosed cytotoxic agents (i.e., drug moieties) are conjugated to an antibody via either a Cys or a Lys residue. For Lys conjugation, the DAR (drug antibody ratio) of the majority of the ADC is 2 whereas the DAR of the majority of ADC is 4 when conjugation occurs on a Cys residue.

Abstract: There is disclosed a Dolastatin derivative, conjugated to an antibody, comprising a Dolastatin derivative moiety of Formula IV.

Abstract: A service processing device and method include receiving a service processing request including data interaction processing mode information and account information, and determining, based on the service processing request, one or more data interaction processing mode candidates for executing the service processing request. The data interaction processing mode candidates are determined from a plurality of data interaction processing modes. Each of the data interaction processing modes includes processing parameters, and at least one of the processing parameters is different between different data interaction processing modes. Each of the one or more data interaction processing mode candidates has an associated processing success rate based on a historical processing record of the data interaction processing modes.

Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.

Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.

Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

Abstract: There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.

Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.

Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.

Abstract: The invention provides nucleotide sequences that can be used in operable association with a promoter to express a polynucleotide sequence of interest in a plant, plant part or plant cell at particular stages of development and/or in specific tissues. and methods for directing developmental stage specific and/or tissue specific expression of a polynucleotide of interest.

Abstract: The present invention provides compounds capable of modulating tyrosine kinases, compositions comprising the compounds and methods of their use.

Abstract: The invention provides nucleotide sequences that can be used in operable association with a promoter to express a polynucleotide of interest in a plant, plant part or plant cell. Also provided are methods of increasing or decreasing the expression of a nucleotide sequence of interest in a plant, plant part or plant cell in response to nitrate, drought and/or rehydration.

Abstract: A system, apparatus, and method are directed towards managing communications with global applications through message handlers. The message is received by a first message handler that is local to the client device. The first message handler determines if the message is to be forwarded to a global application, and if so, forwards the message to a second message handler, which is configured to be local to the global application. The second message handler forwards the message and receives a response from the global application. The second message handler may then generate a session identifier that is useable to manage its session data for the message/response. The session identifier is sent to the first message handler in lieu of sending the session data, such that the two message handlers manage separately their own session data for the session. The session identifier is useable to relate the separately managed session data sets.

Abstract: A system, apparatus, and method are directed towards managing short code allocation policies across a plurality of different carriers for multiple applications. Each carrier provides to a centralized routing service a short code policy that includes an extension allocation policy. The extension allocation policy may specify whether the extensions are allocated based on a dynamical recycle allocation, a range recycle allocation, a pass-through allocation, or a re-usekey based allocation policy, or other mechanism. When a message is sent from an application, a carrier is determined to send the message to a destination mobile device. The carrier's short code policy, including the extension allocation policy, is then used to select how to allocate and/or re-allocate a short code and extension for use with the message. The message may then be modified to include the selected short code and extension, and is then sent using the determined network carrier.